616 related articles for article (PubMed ID: 14614021)
1. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin.
Morbidelli L; Donnini S; Chillemi F; Giachetti A; Ziche M
Clin Cancer Res; 2003 Nov; 9(14):5358-69. PubMed ID: 14614021
[TBL] [Abstract][Full Text] [Related]
2. Studies on the structure-activity relationship of endostatin: synthesis of human endostatin peptides exhibiting potent antiangiogenic activities.
Chillemi F; Francescato P; Ragg E; Cattaneo MG; Pola S; Vicentini L
J Med Chem; 2003 Sep; 46(19):4165-72. PubMed ID: 12954068
[TBL] [Abstract][Full Text] [Related]
3. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
4. AIDS-related Kaposi's sarcoma cells rapidly internalize endostatin, which co-localizes to tropomysin microfilaments and inhibits cytokine-mediated migration and invasion.
Mallery SR; Morse MA; Wilson RF; Pei P; Ness GM; Bradburn JE; Renner RJ; Schuller DE; Robertson FM
J Cell Biochem; 2003 May; 89(1):133-43. PubMed ID: 12682914
[TBL] [Abstract][Full Text] [Related]
5. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.
Olsson AK; Johansson I; Akerud H; Einarsson B; Christofferson R; Sasaki T; Timpl R; Claesson-Welsh L
Cancer Res; 2004 Dec; 64(24):9012-7. PubMed ID: 15604266
[TBL] [Abstract][Full Text] [Related]
6. Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model.
Becker CM; Sampson DA; Short SM; Javaherian K; Folkman J; D'Amato RJ
Fertil Steril; 2006 Jan; 85(1):71-7. PubMed ID: 16412733
[TBL] [Abstract][Full Text] [Related]
7. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
8. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin.
Urbich C; Reissner A; Chavakis E; Dernbach E; Haendeler J; Fleming I; Zeiher AM; Kaszkin M; Dimmeler S
FASEB J; 2002 May; 16(7):706-8. PubMed ID: 11978735
[TBL] [Abstract][Full Text] [Related]
9. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells.
He GA; Luo JX; Zhang TY; Hu ZS; Wang FY
Biochem Biophys Res Commun; 2004 May; 318(2):354-60. PubMed ID: 15120609
[TBL] [Abstract][Full Text] [Related]
10. The anti-angiogenic activity of human endostatin inhibits bladder cancer growth and its mechanism.
Du Z; Hou S
J Urol; 2003 Nov; 170(5):2000-3. PubMed ID: 14532841
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of full-length human endostatin on in vitro angiogenesis.
Taddei L; Chiarugi P; Brogelli L; Cirri P; Magnelli L; Raugei G; Ziche M; Granger HJ; Chiarugi V; Ramponi G
Biochem Biophys Res Commun; 1999 Sep; 263(2):340-5. PubMed ID: 10491294
[TBL] [Abstract][Full Text] [Related]
12. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma.
Dhanabal M; Ramchandran R; Volk R; Stillman IE; Lombardo M; Iruela-Arispe ML; Simons M; Sukhatme VP
Cancer Res; 1999 Jan; 59(1):189-97. PubMed ID: 9892206
[TBL] [Abstract][Full Text] [Related]
13. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
14. Increased levels of tissue endostatin in human malignant gliomas.
Morimoto T; Aoyagi M; Tamaki M; Yoshino Y; Hori H; Duan L; Yano T; Shibata M; Ohno K; Hirakawa K; Yamaguchi N
Clin Cancer Res; 2002 Sep; 8(9):2933-8. PubMed ID: 12231538
[TBL] [Abstract][Full Text] [Related]
15. N-/C-terminal deleted mutant of human endostatin efficiently acts as an anti-angiogenic and anti-tumorigenic agent.
Cho H; Kim WJ; Lee YM; Kim YM; Kwon YG; Park YS; Choi EY; Kim KW
Oncol Rep; 2004 Jan; 11(1):191-5. PubMed ID: 14654925
[TBL] [Abstract][Full Text] [Related]
16. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases.
Heljasvaara R; Nyberg P; Luostarinen J; Parikka M; Heikkilä P; Rehn M; Sorsa T; Salo T; Pihlajaniemi T
Exp Cell Res; 2005 Jul; 307(2):292-304. PubMed ID: 15950618
[TBL] [Abstract][Full Text] [Related]
17. Involvement of MAPKs in endostatin-mediated regulation of blood-retinal barrier function.
Campbell M; Collery R; McEvoy A; Gardiner TA; Stitt AW; Brankin B
Curr Eye Res; 2006 Dec; 31(12):1033-45. PubMed ID: 17169842
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo.
Jin X; Bookstein R; Wills K; Avanzini J; Tsai V; LaFace D; Terracina G; Shi B; Nielsen LL
Cancer Gene Ther; 2001 Dec; 8(12):982-9. PubMed ID: 11781661
[TBL] [Abstract][Full Text] [Related]
19. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
20. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor.
Ramesh R; Mhashilkar AM; Tanaka F; Saito Y; Branch CD; Sieger K; Mumm JB; Stewart AL; Boquoi A; Dumoutier L; Grimm EA; Renauld JC; Kotenko S; Chada S
Cancer Res; 2003 Aug; 63(16):5105-13. PubMed ID: 12941841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
